GOOGL vs MRK: Which Is the Better Buy?
Side-by-side comparison of Alphabet Inc. and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
Alphabet Inc. · Communication Services
$317.41
-4.5% upside to fair value
Grade D
High Quality
VS
Merck & Co., Inc. · Healthcare
$121.42
-2.9% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
MRK has more upside to fair value
(-2.9%).
MRK trades at a lower forward P/E
(14.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
GOOGL |
MRK |
| Current Price |
$317.41 |
$121.42 |
| Fair Value Estimate |
$303.05 |
$118.00 |
| Upside to Fair Value |
-4.5%
|
-2.9%
|
| Market Cap |
$3,839.7B |
$300.2B |
| Forward P/E |
29.0x
|
14.0x
|
| EV / EBITDA |
21.5x
|
11.8x
|
| Price / Sales |
9.5x
|
4.1x
|
| Price / FCF |
52.4x
|
21.4x
|
| Revenue Growth YoY |
+11.3%
|
+1.3%
|
| Gross Margin |
59.7%
|
81.5%
|
| Operating Margin |
32.0%
|
41.2%
|
| Return on Equity |
35.0%
|
34.7%
|
| Dividend Yield |
0% |
3.1% |
| FCF Yield |
1.91%
|
4.7%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Alphabet Inc. operates as a global leader in internet content and information services, primarily through its dominant search engine, advertising platforms, and cloud computing services. The company benefits from durable competitive moats including browser and mobile OS dominance, strong brand recognition, and advanced AI infrastructure investments. Despite strong revenue growth of 11.3% year-ove…
Merck is a top-5 global pharmaceutical company generating $65B in annual revenue with 81.5% gross margins and 28% net margins. Keytruda, the world's best-selling drug at $31.7B (49% of pharma revenue), faces patent expiry in 2028. Merck is aggressively building replacements through M&A and pipeline launches: Winrevair ($1.4B year one), Capvaxive ($759M), and the $6.7B Terns acquisition for TERN-7…
Accumulation Zones
| Metric |
GOOGL |
MRK |
| Zone Low |
$227.29 |
$88.00 |
| Zone High |
$257.59 |
$100.00 |
| In Buy Zone? |
No
|
No
|